Egyptian International Pharmaceutical Industries (EIPICO) achieved a consolidated net profit of EGP 823.3 million in 2023, marking a notable increase from EGP 643.76 million in 2022. The company’s net sales skyrocketed to EGP 5.23 billion, up from EGP 3.95 billion the previous year. Standalone results also showed growth, with net profit rising to EGP 730.08 million from EGP 589.15 million, and revenues hitting EGP 5.01 billion compared to EGP 3.79 billion in 2022. However, earnings per share (EPS) dipped slightly to EGP 5.15 in 2023 from EGP 5.94 in 2022. Notably, EIPICO crossed EGP 5 billion in total sales for the year, with consolidated net profits in the first nine months of 2023 surging to EGP 644.14 million from EGP 417.79 million in the same period of 2022.